The Oncology Institute shares surge 26.14% after-hours as Q3 revenue beats estimates, EBITDA turns positive, and guidance raised.

The Oncology Institute, Inc. surged 26.14% in after-hours trading following the release of its third-quarter 2025 results, which highlighted stronger-than-expected revenue performance and a pivotal shift to positive adjusted EBITDA. The company reported $136.6 million in total revenue, exceeding estimates of $122.5 million, driven by growth in Patient Services and Dispensary segments. Notably, adjusted EBITDA turned positive at $3.5 million, marking a first-time milestone. Management also raised full-year revenue guidance and confirmed Adjusted EBITDA and Free Cash Flow forecasts, bolstered by $27.7 million in cash reserves as of September 30. These developments signaled improved financial health and operational momentum, aligning with the stock’s sharp after-hours rebound.